YAP1 and neoplasm: Increased YAP activity and decreased ERK1/2 activity was observed in a patient-derived xenograft in vivo model from tumour tissue sampled from a patient with EGFR-mutant NSCLC who had undergone partial response following treatment with osimertinib and selumetinib (24).